(Q48484600)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Roberto Piro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Nicola Facciolongo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Debora Formisano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Alberto Roggeri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Anna Simonazzi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Claudia Castagnetti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Cristiano Carbonelli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Luigi Zucchi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

9 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic advances in respiratory disease

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

87-95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

Italian real-life experience of omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

Reduction of the total IgE level by omalizumab in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

Anti-IgE for chronic asthma in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465811429478

21 January 2018

Identifiers

DOI

10.1177/1753465811429478

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22323442%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference